Zoetis Inc. (NYSE:ZTS) Stock Position Lowered by TFG Advisers LLC

TFG Advisers LLC trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 5.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,931 shares of the company’s stock after selling 211 shares during the period. TFG Advisers LLC’s holdings in Zoetis were worth $640,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in ZTS. Pensionfund Sabic grew its holdings in shares of Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after buying an additional 4,000 shares in the last quarter. PFW Advisors LLC acquired a new stake in Zoetis during the 4th quarter worth about $1,764,000. JPMorgan Chase & Co. grew its stake in Zoetis by 10.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after acquiring an additional 279,092 shares in the last quarter. Simplify Asset Management Inc. acquired a new position in shares of Zoetis in the 3rd quarter valued at about $11,684,000. Finally, Nordea Investment Management AB increased its holdings in shares of Zoetis by 38.3% in the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after purchasing an additional 572,511 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently commented on the stock. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. JPMorgan Chase & Co. boosted their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Morgan Stanley dropped their price target on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. UBS Group started coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Finally, Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $215.00.

Zoetis Stock Down 1.6 %

ZTS opened at $171.37 on Friday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The business has a 50 day moving average price of $169.34 and a 200 day moving average price of $179.28. The firm has a market cap of $77.32 billion, a P/E ratio of 32.21, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio is currently 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.